Featured Publications
Oropharyngeal Carcinoma
Husain Z, Kang J, Lee N, Poon I. Oropharyngeal Carcinoma. Practical Guides In Radiation Oncology 2022, 15-25. DOI: 10.1007/978-3-030-99590-4_2.Peer-Reviewed Original ResearchLong-term treatment toxicityOropharyngeal squamous cell carcinomaCurative treatment optionSquamous cell carcinomaPatterns of failureElective coverageOropharyngeal carcinomaTreatment toxicityNeck malignanciesAccurate target delineationCell carcinomaDisease stageTreatment optionsCurative potentialPhysical examCommon headClinical scenariosRadiation oncologistsSurgical anatomyTarget volumeTarget delineationVolume coverageCarcinomaMultimodal imagingPrimary target
2022
Physician Graded Toxicity Profiles and Survival Outcomes among Patients with Non-Metastatic Oropharyngeal Carcinoma Treated with Proton Therapy vs. Intensity-Modulated Radiation Therapy
Youssef I, Yoon J, Zakeri K, Cohen M, Wong R, Yu Y, Kang J, Gelblum D, McBride S, Sherman E, Dunn L, Cracchiolo J, Chen L, Lee N. Physician Graded Toxicity Profiles and Survival Outcomes among Patients with Non-Metastatic Oropharyngeal Carcinoma Treated with Proton Therapy vs. Intensity-Modulated Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e325-e326. DOI: 10.1016/j.ijrobp.2022.07.1399.Peer-Reviewed Original ResearchProgression-free survivalIntensity-modulated radiation therapyOropharyngeal carcinomaAcute gradeIMRT groupLocoregional recurrenceOncologic outcomesAdverse eventsOverall survivalRadiation therapyPT groupSignificant differencesTreatment-related adverse eventsPatient/tumor characteristicsProton therapyCurative-intent radiationGrade 3 dysphagiaPresence of xerostomiaMedian RT doseRetrospective cohort studyProspective Randomized ComparisonPatient-reported outcomesSimilar oncologic outcomesMATERIAL/METHODSReduction of doseEvaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy
Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, Wong RJ, Dunn L, Pfister DG, Sherman EJ, Lee NY. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncology 2022, 8: 364-372. PMID: 35050342, PMCID: PMC8778604, DOI: 10.1001/jamaoncol.2021.6416.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalMetastasis-free survivalOropharyngeal carcinomaConcurrent chemoradiotherapyDe-escalation strategiesRadiotherapy doseTotal doseSubclinical regionsLocoregional controlGross diseaseCohort studyOverall survivalClinical outcomesHuman Papillomavirus–Associated Oropharyngeal CarcinomaHigh-dose cisplatin therapyHPV-positive oropharyngeal carcinomaTarget volumeBilateral level IBGy of radiotherapyPrimary concurrent chemoradiotherapyRetrospective cohort studyFavorable clinical outcomeAmerican Joint CommitteeLong-term follow
2021
The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.
Lee N, Sherman E, Schöder H, McBride S, Yu Y, Kang J, Tsai C, Gelblum D, Boyle J, Singh B, Cohen M, Cracchiolo J, Ganly I, Dunn L, Kriplani A, Fetten J, Michel L, Wong R, Pfister D, Riaz N. The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer. Journal Of Clinical Oncology 2021, 39: 6019-6019. DOI: 10.1200/jco.2021.39.15_suppl.6019.Peer-Reviewed Original ResearchPositron emission tomographyGrade 1Locoregional controlNodal diseaseOropharyngeal carcinomaOPC patientsGrade 2Primary siteGrade 3 adverse eventsWeight lossDe-escalated patientsGross nodal diseaseRecurrent nodal diseaseResolution of hypoxiaSuccessful salvage surgeryExcellent locoregional controlOverall survival rateSpecific treatment responsesPatient-specific treatment responsesConcurrent chemotherapyDefinitive doseMucositis ratesAdditional therapySalvage surgeryAdverse events
2020
Radiation Treatment Breaks: Are They Detrimental to Outcomes for Oropharyngeal Carcinoma Treated with Definitive Chemoradiation?
Rybkin A, Kang J, Lee A, Kitpanit S, Fan M, Mohamed N, Cartano O, Dunn L, Sherman E, Wong R, Tsai C, McBride S, Yu Y, Chen L, Zakeri K, Riaz N, Lee N. Radiation Treatment Breaks: Are They Detrimental to Outcomes for Oropharyngeal Carcinoma Treated with Definitive Chemoradiation? International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e851-e852. DOI: 10.1016/j.ijrobp.2020.07.409.Peer-Reviewed Original ResearchRadical Reduction of Radiation Therapy Dose Prescription for Elective Treatment Areas in Human Papillomavirus (HPV) - Associated Oropharyngeal Carcinoma (OPC)
Tsai C, McBride S, Riaz N, Kang J, Yu Y, Chen L, Gelblum D, Wong R, Boyle J, Dunn L, Sherman E, Pfister D, Lee N. Radical Reduction of Radiation Therapy Dose Prescription for Elective Treatment Areas in Human Papillomavirus (HPV) - Associated Oropharyngeal Carcinoma (OPC). International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1143-1144. DOI: 10.1016/j.ijrobp.2019.11.209.Peer-Reviewed Original Research